Detailed Mechanism Funding and Narrative

Years of mechanism: 2011 2012 2013 2014 2015 2016 2017 2018 2019

Details for Mechanism ID: 12692
Country/Region: Haiti
Year: 2018
Main Partner: Ministre de la Sante Publique et Population - Haiti
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $16,006,875 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,275,788
Care: Orphans and Vulnerable Children (HKID) $1,896,688
Care: TB/HIV (HVTB) $1,201,996
Care: Pediatric Care and Support (PDCS) $310,194
Laboratory Infrastructure (HLAB) $1,150,000
Strategic Information (HVSI) $676,512
Health Systems Strengthening (OHSS) $760,000
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $3,085,625
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $950,465
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $4,145,284
Treatment: Pediatric Treatment (PDTX) $554,323
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 32
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 91
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 104
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 1
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 94
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 19
GEND_GBV 25-29, Male, Sexual Violence (Post-Rape Care) 2019 4
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 14
GEND_GBV 30-34, Male, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 13
GEND_GBV 35-39, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 11
GEND_GBV 40-49, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 393
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 1
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 393
GEND_GBV Number of people receiving post-GBV care 2019 394
HTS_SELF 2019 1,850
HTS_SELF 15-19, Female, Directly-Assisted 2019 66
HTS_SELF 15-19, Female, Unassisted 2019 66
HTS_SELF 15-19, Male, Directly-Assisted 2019 66
HTS_SELF 15-19, Male, Unassisted 2019 66
HTS_SELF 20-24, Female, Directly-Assisted 2019 66
HTS_SELF 20-24, Female, Unassisted 2019 66
HTS_SELF 20-24, Male, Directly-Assisted 2019 66
HTS_SELF 20-24, Male, Unassisted 2019 66
HTS_SELF 25-29, Female, Directly-Assisted 2019 66
HTS_SELF 25-29, Female, Unassisted 2019 66
HTS_SELF 25-29, Male, Directly-Assisted 2019 66
HTS_SELF 25-29, Male, Unassisted 2019 66
HTS_SELF 30-34, Female, Directly-Assisted 2019 66
HTS_SELF 30-34, Female, Unassisted 2019 66
HTS_SELF 30-34, Male, Directly-Assisted 2019 66
HTS_SELF 30-34, Male, Unassisted 2019 66
HTS_SELF 35-39, Female, Directly-Assisted 2019 66
HTS_SELF 35-39, Female, Unassisted 2019 66
HTS_SELF 35-39, Male, Directly-Assisted 2019 66
HTS_SELF 35-39, Male, Unassisted 2019 66
HTS_SELF 40-49, Female, Directly-Assisted 2019 66
HTS_SELF 40-49, Female, Unassisted 2019 66
HTS_SELF 40-49, Male, Directly-Assisted 2019 66
HTS_SELF 40-49, Male, Unassisted 2019 66
HTS_SELF 50+, Female, Directly-Assisted 2019 66
HTS_SELF 50+, Female, Unassisted 2019 66
HTS_SELF 50+, Male, Directly-Assisted 2019 67
HTS_SELF 50+, Male, Unassisted 2019 67
HTS_SELF Directly-Assisted 2019 925
HTS_SELF Unassisted 2019 925
HTS_SELF Unassisted - Other 2019 296
HTS_SELF Unassisted - Self 2019 296
HTS_SELF Unassisted - Sex Partner 2019 333
HTS_TST <5, Unknown Sex, Negative 2019 612
HTS_TST 25-29, Female, Negative 2019 975
HTS_TST 25-29, Female, Negative 2019 308
HTS_TST 25-29, Female, Negative 2019 1,528
HTS_TST 25-29, Female, Negative 2019 8,952
HTS_TST 25-29, Female, Negative 2019 116
HTS_TST 25-29, Female, Negative 2019 10,967
HTS_TST 25-29, Male, Negative 2019 504
HTS_TST 25-29, Male, Negative 2019 170
HTS_TST 25-29, Male, Negative 2019 784
HTS_TST 25-29, Male, Negative 2019 60
HTS_TST 25-29, Male, Negative 2019 5,589
HTS_TST 30-34, Female, Negative 2019 975
HTS_TST 30-34, Female, Negative 2019 308
HTS_TST 30-34, Female, Negative 2019 1,528
HTS_TST 30-34, Female, Negative 2019 8,952
HTS_TST 30-34, Female, Negative 2019 116
HTS_TST 30-34, Female, Negative 2019 10,967
HTS_TST 30-34, Male, Negative 2019 504
HTS_TST 30-34, Male, Negative 2019 170
HTS_TST 30-34, Male, Negative 2019 784
HTS_TST 30-34, Male, Negative 2019 60
HTS_TST 30-34, Male, Negative 2019 5,589
HTS_TST 35-39, Female, Negative 2019 975
HTS_TST 35-39, Female, Negative 2019 308
HTS_TST 35-39, Female, Negative 2019 1,528
HTS_TST 35-39, Female, Negative 2019 8,952
HTS_TST 35-39, Female, Negative 2019 116
HTS_TST 35-39, Female, Negative 2019 10,967
HTS_TST 35-39, Male, Negative 2019 504
HTS_TST 35-39, Male, Negative 2019 170
HTS_TST 35-39, Male, Negative 2019 784
HTS_TST 35-39, Male, Negative 2019 60
HTS_TST 35-39, Male, Negative 2019 5,589
HTS_TST 40-49, Female, Negative 2019 970
HTS_TST 40-49, Female, Negative 2019 315
HTS_TST 40-49, Female, Negative 2019 1,535
HTS_TST 40-49, Female, Negative 2019 8,952
HTS_TST 40-49, Female, Negative 2019 123
HTS_TST 40-49, Female, Negative 2019 10,969
HTS_TST 40-49, Male, Negative 2019 502
HTS_TST 40-49, Male, Negative 2019 171
HTS_TST 40-49, Male, Negative 2019 781
HTS_TST 40-49, Male, Negative 2019 67
HTS_TST 40-49, Male, Negative 2019 5,583
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 183,648
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 1,962
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 4,414
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 6,841
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 158
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 1,765
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 552
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 711
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 122
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 80
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 436
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 194
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 956
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 749
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 59
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 643
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 140
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 260
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 42
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 28
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 158
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 80
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 273
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 207
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 174
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 111
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 611
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 240
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 1,660
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 1,192
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 4,876
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 52
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 16
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 8
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 45
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 17
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 128
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 106
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 1,364
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 887
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 4,683
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 2,000
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 10,713
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 8,648
HTS_TST_POS <5, Unknown Sex, Positive 2019 11
HTS_TST_POS 25-29, Female, Positive 2019 171
HTS_TST_POS 25-29, Female, Positive 2019 6
HTS_TST_POS 25-29, Female, Positive 2019 38
HTS_TST_POS 25-29, Female, Positive 2019 80
HTS_TST_POS 25-29, Female, Positive 2019 12
HTS_TST_POS 25-29, Female, Positive 2019 263
HTS_TST_POS 25-29, Male, Positive 2019 88
HTS_TST_POS 25-29, Male, Positive 2019 2
HTS_TST_POS 25-29, Male, Positive 2019 15
HTS_TST_POS 25-29, Male, Positive 2019 6
HTS_TST_POS 25-29, Male, Positive 2019 136
HTS_TST_POS 30-34, Female, Positive 2019 171
HTS_TST_POS 30-34, Female, Positive 2019 6
HTS_TST_POS 30-34, Female, Positive 2019 38
HTS_TST_POS 30-34, Female, Positive 2019 75
HTS_TST_POS 30-34, Female, Positive 2019 12
HTS_TST_POS 30-34, Female, Positive 2019 263
HTS_TST_POS 30-34, Male, Positive 2019 88
HTS_TST_POS 30-34, Male, Positive 2019 2
HTS_TST_POS 30-34, Male, Positive 2019 15
HTS_TST_POS 30-34, Male, Positive 2019 6
HTS_TST_POS 30-34, Male, Positive 2019 136
HTS_TST_POS 35-39, Female, Positive 2019 171
HTS_TST_POS 35-39, Female, Positive 2019 6
HTS_TST_POS 35-39, Female, Positive 2019 38
HTS_TST_POS 35-39, Female, Positive 2019 78
HTS_TST_POS 35-39, Female, Positive 2019 12
HTS_TST_POS 35-39, Female, Positive 2019 263
HTS_TST_POS 35-39, Male, Positive 2019 88
HTS_TST_POS 35-39, Male, Positive 2019 2
HTS_TST_POS 35-39, Male, Positive 2019 15
HTS_TST_POS 35-39, Male, Positive 2019 6
HTS_TST_POS 35-39, Male, Positive 2019 136
HTS_TST_POS 40-49, Female, Positive 2019 175
HTS_TST_POS 40-49, Female, Positive 2019 12
HTS_TST_POS 40-49, Female, Positive 2019 28
HTS_TST_POS 40-49, Female, Positive 2019 74
HTS_TST_POS 40-49, Female, Positive 2019 23
HTS_TST_POS 40-49, Female, Positive 2019 263
HTS_TST_POS 40-49, Male, Positive 2019 93
HTS_TST_POS 40-49, Male, Positive 2019 11
HTS_TST_POS 40-49, Male, Positive 2019 29
HTS_TST_POS 40-49, Male, Positive 2019 15
HTS_TST_POS 40-49, Male, Positive 2019 133
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 18
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 38
HTS_TST_POS Service Delivery Point (Facility) ANC: 50+, Positive 2019 55
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 37
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 16
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 20
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 79
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 31
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 169
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 134
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 35
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 14
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 38
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 26
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 49
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 22
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 34
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 19
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 119
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 53
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 254
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 199
OVC_SERV Age/Sex: <1 2019 554
OVC_SERV Age/Sex: 1-9 2019 3,185
OVC_SERV Age/Sex: 10-14 Female 2019 1,592
OVC_SERV Age/Sex: 10-14 Male 2019 1,575
OVC_SERV Age/Sex: 15-17 Female 2019 1,290
OVC_SERV Age/Sex: 15-17 Male 2019 1,253
OVC_SERV By: Age/sex: 18-24 Female 2019 1,218
OVC_SERV By: Age/sex: 25+ Female 2019 2,332
OVC_SERV By: Age/sex: Male 18-24 2019 1,160
OVC_SERV By: Age/sex: Male 25+ 2019 1,574
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2019 15,733
OVC_SERV Program Completion: Active 2019 15,268
OVC_SERV Program Completion: Graduation 465 Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner. 7,411 Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2019 15,733
OVC_SERV Sum of Age/Sex disaggregates 2019 5,710
PMTCT_ART Already on ART at beginning of current pregnancy 2019 458
PMTCT_ART New on ART 2019 408
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 866
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 49,885
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 689
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 171
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 860
PMTCT_EID Sum of Infant Age disaggregates 2019 860
PMTCT_STAT 25-29, Female 2019 9,110
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 88
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 8,943
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 79
PMTCT_STAT 30-34, Female 2019 9,104
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 91
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 8,943
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 74
PMTCT_STAT 35-39, Female 2019 9,100
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 91
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 8,943
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 77
PMTCT_STAT 40-49, Female 2019 9,098
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 84
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 8,943
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 73
PMTCT_STAT By Age (Numerator): 15-19 2019 1,997
PMTCT_STAT By Age (Numerator): 20-24 2019 4,490
PMTCT_STAT By Age (Numerator): 50+ 2019 6,986
PMTCT_STAT By Number of known positives: 15-19 2019 20
PMTCT_STAT By Number of known positives: 20-24 2019 45
PMTCT_STAT By Number of known positives: 50+ 2019 70
PMTCT_STAT By Number of new negative: 15-19 2019 1,960
PMTCT_STAT By Number of new negative: 20-24 2019 4,409
PMTCT_STAT By Number of new negative: 50+ 2019 6,834
PMTCT_STAT By Number of new positives: 15-19 2019 18
PMTCT_STAT By Number of new positives: 20-24 2019 38
PMTCT_STAT By Number of new positives: 50+ 2019 55
PMTCT_STAT Number of new ANC and L&D clients 2019 49,885
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 49,885
PMTCT_STAT_den 25-29, Female 2019 9,110
PMTCT_STAT_den 30-34, Female 2019 9,104
PMTCT_STAT_den 35-39, Female 2019 9,100
PMTCT_STAT_den 40-49, Female 2019 9,098
PMTCT_STAT_den By Age (Denominator): <15-19 2019 1,997
PMTCT_STAT_den By Age (Denominator): 20-24 2019 4,490
PMTCT_STAT_den By Age (Denominator): 50+ 2019 6,986
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 1
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 57
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 35
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 93
TB_PREV By Age/Sex (Numerator): <15, Female 2019 125
TB_PREV By Age/Sex (Numerator): <15, Male 2019 85
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 2,538
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 1,482
TB_PREV IPT, Life-long ART, New, Positive 2019 4,230
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 4,230
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 4,701
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 141
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 93
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 2,819
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 1,648
TB_PREV_den IPT, Life-long ART, New, Positive 2019 4,701
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 39
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 773
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 25
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 454
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period. 2019 1,291
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 1,291
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 39
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 773
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 25
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 454
TX_CURR 25-29, Female, Positive 2019 3,197
TX_CURR 25-29, Male, Positive 2019 1,669
TX_CURR 30-34, Female, Positive 2019 3,197
TX_CURR 30-34, Male, Positive 2019 1,669
TX_CURR 35-39, Female, Positive 2019 3,197
TX_CURR 35-39, Male, Positive 2019 1,669
TX_CURR 40-49, Female, Positive 2019 3,197
TX_CURR 40-49, Male, Positive 2019 1,669
TX_CURR Age/Sex: <1 2019 72
TX_CURR Age/Sex: <1-9 2019 834
TX_CURR Age/Sex: 10-14 Female 2019 317
TX_CURR Age/Sex: 10-14 Male 2019 260
TX_CURR Age/Sex: 15-19 Female 2019 404
TX_CURR Age/Sex: 15-19 Male 2019 265
TX_CURR Age/Sex: 20-24 Female 2019 1,448
TX_CURR Age/Sex: 20-24 Male 2019 673
TX_CURR Age/Sex: 50+ Female 2019 3,166
TX_CURR Age/Sex: 50+ Male 2019 2,457
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 29,360
TX_CURR Sum of age/sex disaggregates 2019 669
TX_NEW 25-29, Female, Positive 2019 575
TX_NEW 25-29, Male, Positive 2019 302
TX_NEW 30-34, Female, Positive 2019 575
TX_NEW 30-34, Male, Positive 2019 302
TX_NEW 35-39, Female, Positive 2019 574
TX_NEW 35-39, Male, Positive 2019 302
TX_NEW 40-49, Female, Positive 2019 573
TX_NEW 40-49, Male, Positive 2019 302
TX_NEW Breastfeeding status 2019 62
TX_NEW By Age/Sex: <1 2019 10
TX_NEW By Age/Sex: 1-9 2019 140
TX_NEW By Age/Sex: 10-14 Female 2019 54
TX_NEW By Age/Sex: 10-14 Male 2019 42
TX_NEW By Age/Sex: 15-19 Female 2019 73
TX_NEW By Age/Sex: 15-19 Male 2019 47
TX_NEW By Age/Sex: 20-24 Female 2019 256
TX_NEW By Age/Sex: 20-24 Male 2019 120
TX_NEW By Age/Sex: 50+ Female 2019 554
TX_NEW By Age/Sex: 50+ Male 2019 459
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 5,260
TX_NEW Pregnancy status 2019 398
TX_NEW Sum of Age/Sex disaggregates 2019 1,605
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 26,890
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 723
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 87
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 474
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 55
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 14,459
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 1,610
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 8,535
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 947
TX_PVLS_den Denominator: Indication: Routine 2019 24,191
TX_PVLS_den Denominator: Indication: Targeted 2019 2,699
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 158
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 100
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 3,079
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,821
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 5,158
TX_RET Numerator by Status: Breastfeeding 2019 62
TX_RET Numerator by Status: Pregnant 2019 518
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 5,158
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 158
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 100
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 3,079
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,821
TX_RET_den Denominator by Status: Breastfeeding 2019 61
TX_RET_den Denominator by Status: Pregnant 2019 512
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 29,362
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 876
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 591
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 17,539
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 10,355
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 464
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2019 40
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 658
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 1,162
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 22,568
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 942
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 5,317
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 224
Cross Cutting Budget Categories and Known Amounts Total: $927,926
Key Populations: MSM and TG $200,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Monitoring and evaluation of MSM/TG programs
Key Populations: Sex Workers $200,000
Collection and use of strategic information on SWs and clients
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Monitoring and evaluation of SW programs
Gender: Gender Based Violence (GBV) $300,000
GBV Prevention
Human Resources for Health $87,500
Adolescent Girls and Young Women (AGYW) $140,426